Bavarian Nordic (BAVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bavarian Nordic (BAVA) has a cash flow conversion efficiency ratio of 0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr1.29 Billion ≈ $202.44 Million USD) by net assets (Dkr13.16 Billion ≈ $2.06 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bavarian Nordic - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Bavarian Nordic's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Bavarian Nordic for a breakdown of total debt and financial obligations.
Bavarian Nordic Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bavarian Nordic ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OLAM GROUP LTD
F:K25
|
N/A |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
0.057x |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601
|
0.042x |
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
0.045x |
|
SOC.BIC UNS.ADR1/2/EO382
F:BIF0
|
N/A |
|
Yunnan Shennong Agricultural Industry Group Co Ltd
SHG:605296
|
-0.018x |
|
Ziraat Gayrimenkul Yatirim Ortakligi AS
IS:ZRGYO
|
0.001x |
|
Kayne Anderson MLP Investment Closed Fund
NYSE:KYN
|
0.012x |
Annual Cash Flow Conversion Efficiency for Bavarian Nordic (2001–2024)
The table below shows the annual cash flow conversion efficiency of Bavarian Nordic from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see Bavarian Nordic (BAVA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Dkr11.41 Billion ≈ $1.78 Billion |
Dkr1.95 Billion ≈ $305.07 Million |
0.171x | +57.90% |
| 2023-12-31 | Dkr10.34 Billion ≈ $1.62 Billion |
Dkr1.12 Billion ≈ $175.11 Million |
0.108x | +251.70% |
| 2022-12-31 | Dkr7.15 Billion ≈ $1.12 Billion |
Dkr220.05 Million ≈ $34.43 Million |
0.031x | +163.31% |
| 2021-12-31 | Dkr7.37 Billion ≈ $1.15 Billion |
Dkr-358.50 Million ≈ $-56.09 Million |
-0.049x | -141.60% |
| 2020-12-31 | Dkr4.89 Billion ≈ $765.76 Million |
Dkr571.91 Million ≈ $89.48 Million |
0.117x | +179.00% |
| 2019-12-31 | Dkr1.87 Billion ≈ $291.86 Million |
Dkr-275.91 Million ≈ $-43.17 Million |
-0.148x | -11.78% |
| 2018-12-31 | Dkr2.18 Billion ≈ $341.18 Million |
Dkr-288.53 Million ≈ $-45.14 Million |
-0.132x | -253.48% |
| 2017-12-31 | Dkr2.51 Billion ≈ $392.13 Million |
Dkr216.06 Million ≈ $33.80 Million |
0.086x | -35.01% |
| 2016-12-31 | Dkr2.02 Billion ≈ $315.61 Million |
Dkr267.60 Million ≈ $41.87 Million |
0.133x | +69.09% |
| 2015-12-31 | Dkr1.34 Billion ≈ $210.04 Million |
Dkr105.32 Million ≈ $16.48 Million |
0.078x | -71.00% |
| 2014-12-31 | Dkr1.25 Billion ≈ $195.90 Million |
Dkr338.75 Million ≈ $53.00 Million |
0.271x | +79.58% |
| 2013-12-31 | Dkr976.29 Million ≈ $152.75 Million |
Dkr147.08 Million ≈ $23.01 Million |
0.151x | +649.29% |
| 2012-12-31 | Dkr999.68 Million ≈ $156.41 Million |
Dkr20.10 Million ≈ $3.14 Million |
0.020x | +106.47% |
| 2011-12-31 | Dkr1.21 Billion ≈ $188.94 Million |
Dkr-375.24 Million ≈ $-58.71 Million |
-0.311x | -4.99% |
| 2010-12-31 | Dkr810.43 Million ≈ $126.80 Million |
Dkr-239.86 Million ≈ $-37.53 Million |
-0.296x | +56.95% |
| 2009-12-31 | Dkr704.21 Million ≈ $110.18 Million |
Dkr-484.14 Million ≈ $-75.75 Million |
-0.687x | -3214.05% |
| 2008-12-31 | Dkr1.02 Billion ≈ $158.82 Million |
Dkr22.41 Million ≈ $3.51 Million |
0.022x | -83.52% |
| 2007-12-31 | Dkr1.22 Billion ≈ $190.51 Million |
Dkr163.16 Million ≈ $25.53 Million |
0.134x | +147.63% |
| 2006-12-31 | Dkr691.40 Million ≈ $108.17 Million |
Dkr-194.49 Million ≈ $-30.43 Million |
-0.281x | -204.50% |
| 2005-12-31 | Dkr630.10 Million ≈ $98.58 Million |
Dkr-58.21 Million ≈ $-9.11 Million |
-0.092x | +61.98% |
| 2004-12-31 | Dkr315.39 Million ≈ $49.35 Million |
Dkr-76.63 Million ≈ $-11.99 Million |
-0.243x | -40386.52% |
| 2003-12-31 | Dkr347.00 Million ≈ $54.29 Million |
Dkr209.27K ≈ $32.74K |
0.001x | +100.86% |
| 2002-12-31 | Dkr196.44 Million ≈ $30.73 Million |
Dkr-13.71 Million ≈ $-2.15 Million |
-0.070x | +96.69% |
| 2001-12-31 | Dkr44.14 Million ≈ $6.91 Million |
Dkr-93.12 Million ≈ $-14.57 Million |
-2.109x | -- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more